In the last trading session, 1.02 million Candel Therapeutics Inc (NASDAQ:CADL) shares changed hands as the company’s beta touched -1.05. With the company’s per share price at $8.75 changed hands at $0.81 or 10.20% during last session, the market valuation stood at $389.16M. CADL’s last price was a discount, traded about -66.86% off its 52-week high of $14.60. The share price had its 52-week low at $1.34, which suggests the last value was 84.69% up since then. When we look at Candel Therapeutics Inc’s average trading volume, we note the 10-day average is 0.82 million shares, with the 3-month average coming to 1.79 million.
Analysts gave the Candel Therapeutics Inc (CADL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CADL as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Candel Therapeutics Inc’s EPS for the current quarter is expected to be -0.24.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Instantly CADL was in green as seen at the end of in last trading. With action 5.93%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 0.81%, with the 5-day performance at 5.93% in the green. However, in the 30-day time frame, Candel Therapeutics Inc (NASDAQ:CADL) is 2.34% up. Looking at the short shares, we see there were 3.34 million shares sold at short interest cover period of 2.54 days.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -43.86%. The 2025 estimates are for Candel Therapeutics Inc earnings to increase by 29.34%, but the outlook for the next 5-year period is at 24.13% per year.
CADL Dividends
Candel Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Mar-12.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 18.54% of Candel Therapeutics Inc shares while 44.12% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 54.16%. There are 44.12% institutions holding the Candel Therapeutics Inc stock share, with NORTHPOND VENTURES, LLC the top institutional holder. As of 2024-06-30, the company held 6.477% of the shares, roughly 1.94 million CADL shares worth $12.0 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 2.819% or 0.82 million shares worth $5.1 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund . With 3.92 shares estimated at $34.26 million under it, the former controlled 12.06% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.67% of the shares, roughly 866.65 shares worth around $7.58 million.
